Date: 2015-12-10
Type of information: Collaboration agreement
Compound: diabetes care solutions built on the Watson Health Cloud
Company: Novo Nordisk (Denmark) IBM (USA - NY)
Therapeutic area: Metabolic diseases
Type agreement: collaboration
Action mechanism:
Disease: diabetes
Details: * On December 10, 2015, Novo Nordisk and IBM Watson Health announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The companies will explore possibilities for improved diabetes care via insights from real-time, real-world evidence of Novo Nordisk diabetes treatments and devices. By harnessing the potential of the Watson Health Cloud, Novo Nordisk aims to further advance its offerings to people living with diabetes and their healthcare professionals.
IBM Watson is the first commercially available cognitive computing platform and represents a new era of computing. The platform, delivered through the cloud, processes vast amounts of big data to uncover patterns and insights, understands complex questions posed in natural language, proposes evidence-based answers, and learns from each interaction. The Watson Health Cloud is a development platform for health and wellness solutions.
Financial terms:
Latest news:
